

Publikationsliste Dezember 2021

Originalbeiträge in Fachzeitschriften (peer-reviewed)

Goetz G, Hawlik K, Wild C. (2021) Extracorporeal Cytokine Adsorption Therapy As a Preventive Measure in Cardiac Surgery and As a Therapeutic Add-On Treatment in Sepsis: An Updated Systematic Review of Comparative Efficacy and Safety. Crit Care Med. 2021 Aug 1;49(8):1347-1357.

Stanak, M., & Hawlik, K. (2019). Decision-making at the limit of viability: the Austrian neonatal choice context. BMC pediatrics, 19(1), 204.

Stanak, M., Erdos, J., Hawlik, K., & Birsan, T. (2018). Novel Surgical Treatments for Gastroesophageal Reflux Disease: Systematic Review of Magnetic Sphincter Augmentation and Electric Stimulation Therapy. Gastroenterology research, 11(3), 161.

Rosian, K., Hawlik, K., & Piso, B. (2018). Efficacy Assessment of Radiofrequency Ablation as a Palliative Pain Treatment in Patients with Painful Metastatic Spinal Lesions: A Systematic Review. Pain physician, 21, E467-E476.

Hawlik K, Rummel P, Wild C. (2017) Analysis of duplication and timing of health technology assessments on medical devices in Europe. International Journal of Technology Assessment in Health Care. Cambridge University Press; 2017;:1–9.; <http://bit.ly/2Bvbkjv>

Wissenschaftliche Gutachten/ Forschungsberichte

Götz, G. und Hawlik, K. (2020): Extrakorporale Zytokin Adsorption bei Sepsis und SIRS. Update 2020. Decision Support Document 106/ Update 2020.

Hawlik K, Stanak M (2017): Perinatal care at the threshold of viability Part I: Systematic Analysis of Outcomes and Resource Needs for Neonatal Intensive Care Units to inform Health Care Planning. LBI-HTA Projektbericht Nr.: 97a;2017. Wien: Ludwig Boltzmann Institut für Health Technology Assessment.

Stanak M, Hawlik K (2017): Perinatal Care at the threshold of viability: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs). LBI-HTA Project No.: 97b; 2017. Wien: Ludwig Boltzmann Institute for Health Technology Assessment.

Hawlik K, Wild C. Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS, Decision Support Document No.106; 2017. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

Stanak M, Hawlik K (2017): Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD). Decision Support Document No. 104; 2017. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

Rummel P, Hawlik K, Wild C (2016): Health Technology Assessments on Medical Devices in Europe. Final Report. LBI-HTA Rapid Assessment Nr. 12; Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

Hawlik K, Devalière A (2016): Access to High-priced Medicines in Hospital Settings in Europe-A Study in Four European Countries; Research Report, Health Action International

Populärwissenschaftliche Artikel/ Konferenzbeiträge/ Newsletterbeiträge

Auer CM, Rest V, Hawlik K, (2019): 'Public Investments in R&D for new Antibiotics: A call for smart and bold leadership'; AMR Control 2019

Piso, Brigitte; Zechmeister-Koss, Ingrid; Mayer-Ferbas, Julia; Hawlik, Katharina (2018): *Joint HTA for all Societies - Wunschvorstellung oder Schreckensgespenst?* 21. Wissenschaftliche Tagung der Österreichischen Gesellschaft für Public Health, 23. Mai 2018, Wien.

Rummel, P., Wild, C., & Hawlik, K. (2017). OP50 European Assessments Of Medical Devices: Avenues For Improvement. *International Journal of Technology Assessment in Health Care*, 33(S1), 23-24.

Hawlik K (2017): Zukunftsszenarien für nachhaltige Preisgestaltung bei hochpreisigen Medikamenten, HTA-Newsletter September 2017.

Hawlik K (2017): Zytokinfiter zur Therapie der Sepsis, HTA-Newsletter Juli/August 2017.

Erdös J, Hawlik K (2017): Repetitive transkranielle magnetische Stimulation zur Behandlung therapieresistenter Depression, HTA-Newsletter Juli/August 2017.

Hawlik K (2017): Elektrische Stimulationstherapie bei gastroösophagealer Refluxkrankheit, HTA-Newsletter Juli/August 2017.

Hawlik K (2017): Methoden und Definitionen zu „Unmet needs in healthcare“, HTA-Newsletter April 2017.

Hawlik K (2016): HTA von Medizinprodukten in Europa: Schwierigkeiten und Ausblick, HTA-Newsletter November 2016.

Hawlik K, Devalière A (2015): Access to high-priced new medicines: an increasing burden for government health budgets. in *MTb Bulletin of the Netherlands Society for Tropical Medicine and International Health*, 09/2015, p.8;

Ausgewählte Vorträge (seit 2016)

Hawlik, K (2019), Keynote Speech, ‘Public Research for Public Health Needs- the Role of Universities’; Annual Conference Universities Allied for Essential Medicines, April 2019; Hamburg

Hawlik, K (2019), ‘A research agenda for public health?’ Workshop, Annual Conference Universities Allied for Essential Medicines, April 2019; Hamburg

Hawlik K, Rest V (2019): ‚Aktuelle Herausforderungen in der Pharma-Agenda - Aktivitäten der österreichischen Ratspräsidentschaft‘; Pharma- Plattform, Gesundheit Österreich GmbH, Wien

Hawlik K, Piso P (2019): ‚Vorschlag der Europäischen Kommission zur Bewertung der Gesundheitstechnologien (HTA) – Arbeiten unter österreichischen Vorsitz‘; Pharma- Plattform, Gesundheit Österreich GmbH, Wien

Hawlik K (2017): ‘The new medical device legislation- Where can we find more alignment with the new legislation?’, Panel discussion, ISPOR 37th HTA Roundtable [Europe], ISPOR 20th Annual European Congress, 5-8 November, 2017

Hawlik K, Rummel P, Wild C (2017): ‘European Assessments of Medical Devices: Avenues for Improvement’, Oral Presentation, HTAi 2017, Annual Meeting; Rom: 17.-21.06 2017

Hawlik K (2017) ‘ISPOR international initiatives on the assessment of the value of medical technologies’, Panel discussion, Third WHO Global Forum on Medical Devices, 10-12 March, Geneva

Hawlik K, Martin M (2016): Workshops: ‘Advocacy and campaign strategies towards a change in the current R&D system’, Summer School on ‘Access to Medicines and Rational Use’, Health Projects Latvia, Health Action International; Riga: 5-8.7.2016

Hawlik K (2016): ‘Where do we stand on pricing for paediatric oncology medicines?’ Technical Expert Meeting on Paediatric Medicines, World Health Organisation; Geneva: 05.05.2016